



# Discovery of New Genes Involved in Curli Production by a Uropathogenic *Escherichia coli* Strain from the Highly Virulent O45:K1:H7 Lineage

Nguyen Thi Khanh Nhu,<sup>a,b,c</sup>  Minh-Duy Phan,<sup>a,b</sup> Kate M. Peters,<sup>a,b</sup> Alvin W. Lo,<sup>a,b</sup> Brian M. Forde,<sup>a,b,c</sup> Teik Min Chong,<sup>d</sup> Wai-Fong Yin,<sup>d</sup>  Kok-Gan Chan,<sup>d,e</sup> Milan Chromek,<sup>f,g</sup> Annelie Brauner,<sup>f</sup> Matthew R. Chapman,<sup>h</sup>  Scott A. Beatson,<sup>a,b,c</sup>  Mark A. Schembri<sup>a,b</sup>

<sup>a</sup>School of Chemistry and Molecular Biosciences, the University of Queensland, Brisbane, Queensland, Australia

<sup>b</sup>Australian Infectious Diseases Research Centre, the University of Queensland, Brisbane, Queensland, Australia

<sup>c</sup>Australian Centre for Ecogenomics, the University of Queensland, Brisbane, Queensland, Australia

<sup>d</sup>Division of Genetics and Molecular Biology, Institute of Biological Sciences, Faculty of Sciences, University of Malaya, Kuala Lumpur, Malaysia

<sup>e</sup>International Genome Centre, Jiangsu University, Zhenjiang, China

<sup>f</sup>Department of Microbiology, Tumor and Cell Biology, Division of Clinical Microbiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

<sup>g</sup>Department of Pediatrics, CLINTEC, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden

<sup>h</sup>Department of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, Michigan, USA

**ABSTRACT** Curli are bacterial surface-associated amyloid fibers that bind to the dye Congo red (CR) and facilitate uropathogenic *Escherichia coli* (UPEC) biofilm formation and protection against host innate defenses. Here we sequenced the genome of the curli-producing UPEC pyelonephritis strain MS7163 and showed it belongs to the highly virulent O45:K1:H7 neonatal meningitis-associated clone. MS7163 produced curli at human physiological temperature, and this correlated with biofilm growth, resistance of sessile cells to the human cationic peptide cathelicidin, and enhanced colonization of the mouse bladder. We devised a forward genetic screen using CR staining as a proxy for curli production and identified 41 genes that were required for optimal CR binding, of which 19 genes were essential for curli synthesis. Ten of these genes were novel or poorly characterized with respect to curli synthesis and included genes involved in purine *de novo* biosynthesis, a regulator that controls the Rcs phosphorelay system, and a novel repressor of curli production (referred to as *rcpA*). The involvement of these genes in curli production was confirmed by the construction of defined mutants and their complementation. The mutants did not express the curli major subunit CsgA and failed to produce curli based on CR binding. Mutation of *purF* (the first gene in the purine biosynthesis pathway) and *rcpA* also led to attenuated colonization of the mouse bladder. Overall, this work has provided new insight into the regulation of curli and the role of these amyloid fibers in UPEC biofilm formation and pathogenesis.

**IMPORTANCE** Uropathogenic *Escherichia coli* (UPEC) strains are the most common cause of urinary tract infection, a disease increasingly associated with escalating antibiotic resistance. UPEC strains possess multiple surface-associated factors that enable their colonization of the urinary tract, including fimbriae, curli, and autotransporters. Curli are extracellular amyloid fibers that enhance UPEC virulence and promote biofilm formation. Here we examined the function and regulation of curli in a UPEC pyelonephritis strain belonging to the highly virulent O45:K1:H7 neonatal meningitis-associated clone. Curli expression at human physiological temperature led

Received 5 July 2018 Accepted 10 July 2018 Published 21 August 2018

**Citation** Nhu NTK, Phan M-D, Peters KM, Lo AW, Forde BM, Min Chong T, Yin W-F, Chan K-G, Chromek M, Brauner A, Chapman MR, Beatson SA, Schembri MA. 2018. Discovery of new genes involved in curli production by a uropathogenic *Escherichia coli* strain from the highly virulent O45:K1:H7 lineage. *mBio* 9:e01462-18. <https://doi.org/10.1128/mBio.01462-18>.

**Editor** Sheryl Justice, The Ohio State University School of Medicine

**Copyright** © 2018 Nhu et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Mark A. Schembri, [m.schembri@uq.edu.au](mailto:m.schembri@uq.edu.au).

This article is a direct contribution from a Fellow of the American Academy of Microbiology. Solicited external reviewers: Lynette Cegelski, Stanford University; Andrew Roe, University of Glasgow.

to increased biofilm formation, resistance of sessile cells to the human cationic peptide LL-37, and enhanced bladder colonization. Using a comprehensive genetic screen, we identified multiple genes involved in curli production, including several that were novel or poorly characterized with respect to curli synthesis. In total, this study demonstrates an important role for curli as a UPEC virulence factor that promotes biofilm formation, resistance, and pathogenesis.


**KEYWORDS** *Escherichia coli*, biofilms, curli, urinary tract infection, virulence, virulence regulation

The bacterial biofilm lifestyle is integral to many infections and promotes persistence, protection from host innate immune factors, and resistance to antibiotics. Uropathogenic *Escherichia coli* (UPEC) strains, the major cause of human urinary tract infection (UTI) (1–3), form biofilms on catheters (4–6) and in the bladder, either on the surface of the epithelium or within superficial facet cells in the form of intracellular bacterial communities (IBCs) (7–11). UPEC biofilm formation is mediated by multiple factors, including adhesins such as fimbriae, curli, and autotransporter proteins (12–16), and polysaccharides such as the capsule and cellulose (12, 17).

Curli are amyloid fibers that form a key component of the UPEC extracellular biofilm matrix (18–20). They are also highly proinflammatory (21), induce the formation of immunogenic complexes with DNA to stimulate autoimmune responses (22), and can neutralize human cathelicidin (LL-37), a soluble antimicrobial peptide that protects against UTI (23, 24). Curli synthesis is coordinated via a type VIII secretion system also known as the nucleation-precipitation pathway (25) and requires the expression of seven genes from two divergent operons (*csgBAC* and *csgDEFG*) (25, 26). The *csgBAC* operon encodes the curli major subunit protein CsgA, the curli nucleator protein CsgB, and the periplasmic chaperone CsgC. The *csgDEFG* operon encodes CsgD, a regulator that controls the transcription of curli genes, CsgG, an outer membrane secretion pore essential for curli biogenesis, and CsgEF, curli accessory factors (27–29). Curli production is often linked to the synthesis of cellulose as an additional component of the biofilm matrix. Recent work has shown that *E. coli* cells produce a chemically modified phosphoethanolamine cellulose (30), and this polysaccharide can dampen curli-stimulated immune induction (23, 31).

The control of curli biosynthesis is tightly coordinated by a complex signaling network that involves CsgD and several other regulators (32). The sigma factor RpoS, which controls gene expression during stationary-phase growth and stress, is a positive regulator of curli production (33, 34). Another transcriptional response regulator, MlrA, binds directly to the *csgD* promoter and positively regulates curli production in an RpoS-dependent manner (35, 36). Other regulators that control curli production include the osmotic sensor-response pair OmpR-EnvZ (37, 38), the envelope stress sensor-response pair CpxR-CpxA (37, 39), the Rcs phosphorelay system (40, 41), the histone-like nucleoid-structuring (H-NS) protein (33, 34, 42), and integration host factor (IHF) (33, 34, 42). Curli expression is also activated by the second messenger cyclic-di-GMP, which directly enhances transcription of the *csgD* regulatory gene (43–46).

Most of our knowledge on curli regulation and biosynthesis comes from studies on *E. coli* K-12 strains at growth temperatures below 30°C, and an understanding of their genetic control and contribution to pathogenesis in UPEC at human physiological temperature is lacking. Given that many UPEC strains produce curli at 37°C during human infection (23, 47), we investigated the role of these amyloid fibers in the UPEC pyelonephritis strain MS7163, an LL-37-resistant isolate identified in a previous study (24). We showed that MS7163 produces curli, but not cellulose, and sequencing of its genome revealed the genetic basis of this phenotype. We also demonstrated that curli mediate resistance of sessile cells to LL-37 during MS7163 biofilm growth and enhance colonization of the mouse bladder. The production of curli by MS7163 resulted in binding to the dye Congo red (CR), and we exploited this specific property in combination with transposon mutagenesis and transposon-directed insertion site sequencing




**FIG 1** Phylogenetic relationship of MS7163 and other *E. coli* phylogenetic group B2 strains. The maximum likelihood phylogenetic tree of MS7163 and other strains from *E. coli* phylogroup B2 (listed in Table S2) was reconstructed using kSNP with a k-mer size of 21 and rooted using the *E. coli* phylogroup D strain UMN026 as an outgroup. Branches were colored according to their ST types (Achtman MLST scheme). MS7163 (boldface) clustered into the same group of *E. coli* ST95 and was closely related to NMEC strain S88.

(TraDIS) to identify genes involved in curli biogenesis during growth at 37°C. Our screen identified several novel genes, including genes involved in purine *de novo* biosynthesis and two new regulators, all of which were confirmed to affect curli production through the generation of specific mutants and complementation. Finally, the importance of these genes to UPEC virulence was demonstrated in a mouse UTI model.

## RESULTS

**MS7163 produces curli during growth at 37°C and binds Congo red.** MS7163 is a curli-producing UPEC pyelonephritis strain resistant to LL-37 (24). In line with this phenotype, MS7163 bound strongly to CR following growth at both 37°C and 28°C on YESCA-CR agar (see Materials and Methods). Complete genome sequencing of MS7163 revealed it belongs to the *E. coli* B2 phylogenetic group and multilocus sequence type 95 (ST95). The MS7163 genome comprises a chromosome containing 5,074,586 nucleotides and two large plasmids (pMS7163A, 133,843 bp; pMS7163B, 84,078 bp) (see Fig. S1, Fig. S2, and Data Set S1 in the supplemental material). Whole-genome phylogenetic analysis of MS7163 and other completely sequenced B2 strains (listed in Data Set S2 in the supplemental material) revealed MS7163 clusters in a clade with the reference ST95 strains UTI89, a cystitis strain (48), and APEC-O1, an avian-pathogenic *E. coli* strain (49), and in a subclade with the neonatal meningitis *E. coli* (NMEC) strain S88 (50) (Fig. 1). Because curli production and CR binding by *E. coli* are frequently associated with the synthesis of cellulose, we examined the MS7163 genes involved in cellulose regulation and biosynthesis. MS7163 possessed a mutation in the essential cellulose production gene *bcsA* (with a G deletion at nucleotide 556 of *bcsA* causing its premature termination), leading us to predict that it is unable to produce cellulose. To demonstrate this, we mutated the *csgA* major curli subunit gene (to generate the mutant MS7163*csgA*) and examined the phenotypes of MS7163 and MS7163*csgA* on YESCA-CR agar. In contrast to wild-type (wt) MS7163, MS7163*csgA* did not bind CR, confirming that the production of curli (and not cellulose) is specifically associated with this phenotype (Fig. 2A).

**Curli mediate biofilm formation and resistance of sessile cells to LL-37.** To investigate the role of curli in virulence, we assessed the ability of MS7163 and MS7163*csgA* to form a biofilm in a microtiter plate assay employing two different



**FIG 2** Curli enhance UPEC biofilm formation and virulence. (A) CR staining of wt MS7163 and MS7163csgA. (B) Biofilm formation between the wt MS7163 and the curli knockout mutant MS7163csgA in LB and LB without salt. An asterisk represents a  $P$  value of  $<0.0001$  for a  $t$  test between MS7163 and MS7163csgA; error bars represent standard deviation from three independent replicates. (C) Survival rates between the planktonic and sessile cells after 2 h of incubation in the presence of  $64 \mu\text{g/ml}$  LL-37. Error bars represent standard deviation from three independent replicates. (D) Competitive mixed infection mouse experiment employing a 1:1 mixture of MS7163 and MS7163csgA. (Left panel) Total CFU enumerated from the bladder of infected mice. Each symbol represents the CFU for each mouse, and the median is represented by a horizontal line. (Right panel) Competitive fitness index of bladder colonization. Each symbol represents data from an individual mouse in bladder tissue at 24 h postinfection. Logarithmic values of competitive indices are plotted on the y axis; horizontal bars represent median values. A  $\log_{10}$  fitness index below 0 (shown by the dashed line) indicates that MS7163csgA was at a competitive disadvantage. Statistical significance was determined by the two-tailed Wilcoxon's signed rank test (\*,  $P < 0.05$ ).

growth media. In LB, a condition under which curli are not produced, the ability to form a biofilm was similar for both strains ( $P = 0.0994$ ) (Fig. 2B). In contrast, growth in LB without salt, a condition known to induce curli production, resulted in stronger biofilm formation by MS7163 than MS7163csgA ( $P < 0.0001$ ) (Fig. 2B). To specifically investigate how curli-dependent biofilm formation by MS7163 impacts its resistance to LL-37, we allowed MS7163 to form a biofilm by growth in LB broth without salt, separated planktonic (free-swimming) and sessile (biofilm) cells, and tested their susceptibility to LL-37. In these experiments, following a 2-h incubation in the presence of  $64 \mu\text{g/ml}$  of LL-37, most planktonic cells were killed (survival rate of 0.07%), while sessile cells exhibited significant resistance (survival rate of 30.4%;  $P < 0.0001$ ) (Fig. 2C).

**Curli enhance colonization of the mouse urinary tract.** The role of curli in virulence was also assessed by examining the ability of MS7163 and MS7163csgA to survive in the mouse urinary tract in a competitive colonization experiment. Mice were coinoculated with MS7163 and MS7163csgA strains in a 1:1 ratio. In this mixed infection assay, MS7163 significantly outcompeted MS7163csgA in colonization of the bladder ( $P = 0.0078$ ) (Fig. 2D). Together with our biofilm and LL-37 resistance data, these results demonstrate an important role for curli in virulence.

**Large-scale screening for curli-deficient mutants.** We devised a screen based on CR binding in combination with transposon mutagenesis and TraDIS to define the

**TABLE 1** MS7163 genes required for curli production


Gene name	No. of inserts	No. of reads	Congo red binding <sup>a</sup>		CsgA expression by defined mutant <sup>a</sup>	Product <sup>b</sup>
			Tn5 mutants	Defined mutants		
<b>Known curli regulators</b>						
<i>dksA</i>	2	4,496	–	ND	ND	RNA polymerase-binding transcription factor
<i>ihfB</i>	4	9,172	–	ND	ND	Integration host factor subunit beta
<i>rne</i>	1	2,276	–	ND	ND	RNase E
<i>ihfA</i>	1	2,120	–	ND	ND	Integration host factor subunit alpha
<i>mlrA</i>	9	27,691	–	ND	ND	HTH-type transcriptional regulator
<i>ompR</i>	1	3,126	–	ND	ND	Transcriptional regulatory protein
<b>Curli genes</b>						
<i>csgG</i>	11	44,759	–	ND	ND	Curli secretion channel
<i>csgB</i>	1	2,441	–	ND	ND	Curli minor subunit
<i>csgA</i>	3	9,637	–	ND	ND	Curli major subunit
<b>Purine <i>de novo</i> biosynthesis</b>						
<i>purK</i>	1	2,029	–	–	–	<i>N</i> <sup>5</sup> -Carboxyaminoimidazole ribonucleotide synthase
<i>purF</i>	2	6,421	–	–	–	Amidophosphoribosyl transferase
<i>purM</i>	2	6,906	–	–	–	Phosphoribosylformylglycinamide cyclo-ligase
<i>purL</i>	4	11,161	–	ND	ND	Phosphoribosylformylglycinamide synthase
<i>purD</i>	1	1,422	–	–	–	Phosphoribosylamine-glycine ligase
<i>purH</i>	2	6,899	–	ND	ND	AICAR transformylase/IMP cyclohydrolase
<b>Intergenic regions</b>						
<i>yccT-yccU</i>	2	5,164	–	ND	ND	Intergenic region between <i>yccT</i> and <i>yccU</i>
<i>nudE-yrff</i>	2	5,713	–	ND	ND	Intergenic region between <i>nudE</i> and <i>yrff</i>
<i>rcpA-gadW</i>	3	11,579	–	–	–	Upstream of <i>rcpA</i> and downstream of <i>gadW</i>
<b>Others</b>						
<i>yrff</i>	7	17,067	–	–	–	Putative membrane protein
<i>kdgK_2</i>	2	6,169	–	+	+	2-Dehydro-3-deoxygluconokinase
<i>rscD</i>	5	15,895	–	+	+	Phosphotransferase
<i>wzyE</i>	1	3,302	–	+	+	ECA polysaccharide chain elongation

<sup>a</sup>–, negative phenotype; +, positive phenotype; ND, not done.

<sup>b</sup>HTH, helix-turn-helix; AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide; ECA, enterobacterial common antigen.

genetic basis of curli production by MS6173 at 37°C. MS7163 was subjected to transposon mutagenesis using a mini-Tn5 cassette carrying a chloramphenicol resistance gene, and mutants were screened on YESCA-CR agar supplemented with chloramphenicol. Under these conditions, mutants that did not make curli failed to bind CR and were white, mutants that made reduced levels of curli bound CR weakly and were light red, and mutants that were unaltered in their level of curli production bound CR and were red. In total, ~132,000 mini-Tn5 mutants were screened, from which 71 mutants were identified that were “white” and unable to bind CR and 246 mutants were “light red” and exhibited reduced binding to CR. All of these mutants retained their CR binding phenotype over three successive rounds of subculture on YESCA-CR agar.

**Identification of curli mutants using TraDIS.** The above mutants were examined by TraDIS to enable *en masse* identification of the insertion sites that led to altered CR binding. Analysis of the pooled 246 light red colonies generated 1,004,719 sequence reads that mapped to 105 unique mini-Tn5 insertion sites on the MS7163 chromosome. These insertion sites were further localized to 22 genes and 6 intergenic regions, and included genes involved in LPS biogenesis (*waaGHILPQ*, *wzxE*, and *rfaH*), regulation (*envZ* and *rpoS*), metabolism (*pgm*, *galE*, *pgi*, and *fbp*), sodium transport (*nhaA*), and septum formation (*nlpD* and *amiB*) (see Table S1 in the supplemental material). Similarly, analysis of the pooled 71 white colonies generated 238,182 sequence reads that mapped to 67 unique mini-Tn5 insertion sites. These insertion sites were further localized to 19 genes and 3 intergenic regions (Table 1). Among the 19 genes, nine (47.4%) were well characterized with respect to curli production; these included three genes encoding components of the curli assembly machinery (*csgA*, *csgB*, and *csgG*) and




**FIG 3** Purine *de novo* biosynthesis is required for curli production. (A) Purine *de novo* biosynthesis pathway in *E. coli*, adapted from BioCyc. Genes identified by TraDIS that, when mutated, abrogated curli production are indicated by an asterisk. (B) CR staining of wt MS7163, MS7163*csgA*, defined *pur* mutants, and their complemented strains following growth on YESCA-CR agar. Strains were grown by spotting 5  $\mu$ l of an overnight culture on YESCA-CR agar and incubating the culture for 24 h at 37°C. Mutation of genes in the purine *de novo* biosynthesis abolished CR binding, while complementation restored this phenotype. (C) Western blot analysis of CsgA performed using whole-cell lysates prepared from MS7163 or MS7163*csgA* and *pur* mutants and their complemented strains. Bacteria were grown on YESCA agar for 24 h to induce curli production and treated with formic acid to dissolve polymerized CsgA. Anti-OmpA antibody was used as a loading control. (D) CR staining of wt MS7163, MS7163*csgA*, MS7163*purM*, and MS7163*purK* following growth on YESCA-CR agar with (+) and without (-) IMP supplementation.

six genes associated with curli regulation (*mlrA*, *ihfA*, *ihfB*, *dksA*, *rne*, and *ompR*). The remaining ten genes were novel or poorly characterized with respect to curli synthesis, and thus we focused the remainder of our investigation on these genes.

**Disruption of genes involved in purine *de novo* biosynthesis prevents curli production.** Six of the 19 genes identified in our TraDIS analysis (31.6%) form part of the purine *de novo* biosynthesis pathway: i.e., *purF*, *purD*, *purL*, *purM*, *purK*, and *purH* (Table 1). The purine *de novo* biosynthesis pathway comprises 10 genes for the conversion of 5-phospho- $\alpha$ -D-ribose 1-diphosphate (PRPP) to ribosylhypoxanthine monophosphate (IMP), the precursor for AMP and GMP (Fig. 3A). To validate this finding, we examined the involvement of selected purine biosynthesis genes in curli production using defined knockout mutants. Four *pur* mutants were generated by  $\lambda$ -Red-mediated homologous recombination: MS7163*purF*, MS7163*purD*, MS7163*purM*, and MS7163*purK*. Compared to wt MS7163, all four *pur* mutants were unable to bind CR following growth on YESCA-CR agar and failed to express the CsgA major subunit protein based on Western blot analysis of whole-cell lysates employing a CsgA-specific antibody (Fig. 3B and C). Furthermore, complementation of the corresponding gene in each *pur* mutant restored curli production (Fig. 3B and C). Finally, supplementation with IMP, the last product of the purine *de novo* biosynthesis pathway, restored curli production in MS7163*purM* and MS7163*purK* (Fig. 3D). Taken together, these results demonstrate that purine *de novo* biosynthesis plays a critical role in curli production.


**Disruption of *yrfF* prevents curli production.** TraDIS analysis identified seven independent insertions within the *yrfF* gene and two insertions immediately upstream of the *yrfF* coding region, strongly suggesting the involvement of Yrff in curli production. Yrff, also known as IgaA in *Salmonella enterica*, is a negative regulator of the Rcs phosphorelay system, which controls genes involved in colanic acid production (51, 52). Mutation of *yrfF* causes overexpression of the Rcs system, leading to increased colanic acid synthesis (53). To confirm the role of *yrfF* in curli production, we mutated the *yrfF*



**FIG 4** The involvement of the *yrfF* gene in curli production. (A) CR staining of wt MS7163, MS7163*csgA*, MS7163*yrfF*, and the complemented strain MS7163*yrfF*(pYrfF) following growth on YESCA-CR agar. Strains were grown by spotting 5  $\mu$ l of an overnight culture on YESCA-CR agar and incubating for 24 h. Mutation of *yrfF* abolished CR binding and increased mucoidy, while complementation restored the phenotype to the wild type. (B) Western blot analysis of CsgA performed using whole-cell lysates prepared from MS7163, MS7163*yrfF*, and MS7163*yrfF*(pYrfF). Bacteria were grown on YESCA agar for 24 h to induce curli production and treated with formic acid to dissolve polymerized CsgA. Anti-OmpA antibody was used as a loading control. (C) Impact of *yrfF* on the transcription of genes involved in curli biosynthesis, the Rcs phosphorelay system, and colanic acid production. Shown are the relative fold changes in transcript level of curli genes (*csgD* and *csgA*), Rcs phosphorelay system genes (*rcsCDB-A-F*), and the colanic acid biosynthesis gene *wcaH* in MS7163*yrfF* and the complemented MS7163*yrfF*(pYrfF) strain compared to wt MS7163 as determined by qRT-PCR. Total mRNA was extracted from bacteria grown on YESCA agar at 37°C for 24 h. Results are displayed as the mean log<sub>2</sub> FC with standard deviation from three independent replicates.

gene to generate MS7163*yrfF*. MS7163*yrfF* colonies were mucoid and white on YESCA-CR agar, confirming the overexpression of colanic acid and the absence of curli (Fig. 4A). In addition, complementation of MS7163*yrfF* with a plasmid containing the *yrfF* gene (pYrfF) led to loss of mucoidy and restoration of curli production, demonstrated by CR binding and anti-CsgA Western blot analysis (Fig. 4A and B). We also examined the transcription of colanic acid regulatory and biosynthesis genes (*rcsCDB-A-F* and *wcaH*) and selected curli genes (*csgD* and *csgA*) in wt MS7163 compared to MS7163*yrfF* and the complemented strain MS7163*yrfF*(pYrfF). Consistent with our phenotypic data, the transcription of colanic acid genes was increased and curli genes decreased in MS7163*yrfF*, while complementation restored the transcription of these genes to approximately wt level (Fig. 4C). Taken together, these results demonstrate that *yrfF* plays an opposite regulatory role in curli and colanic acid production, respectively.

**Overexpression of the novel regulator RcpA abrogates curli production by repressing the transcription of *csgD* and *csgA*.** Our TraDIS analysis also identified an enrichment of three independent mini-Tn5 insertions in the region upstream of a coding sequence (CDS) identified by the locus tag MS7163\_03831 (at bp -23, -25, and -26 relative to the MS7163\_03831 predicted ATG start codon) (Fig. 5A). In all three cases, the mini-Tn5 cassette was inserted with the chloramphenicol resistance gene in the same orientation as the MS7163\_03831 CDS, referred to henceforth as a repressor of curli production, or *rcpA*. We hypothesized that the mini-Tn5 insertions led to enhanced transcription of the *rcpA* gene via readthrough from the promoter of the chloramphenicol resistance gene within the mini-Tn5, leading to increased expression of RcpA and abolishment of curli production. We tested this by examining the mini-Tn5 mutant with an insertion at position -25 relative to the predicted *rcpA* start codon (referred to as strain Tn5-03831). Indeed, quantitative reverse transcription-PCR (qRT-PCR) analysis revealed that *rcpA* transcript levels in Tn5-03831 were increased ~3.2-fold compared to that in wt MS7163 (Fig. 5B). In contrast, transcript levels of *csgD* and *csgA*




**FIG 5** Overexpression of RcpA abolishes curli production. (A) Schematic overview of genetic constructions in *rcpA*-overexpressing mutants. (i) Tn5-03831 mutant, containing the mini-Tn5 at nucleotide -25 relative to the *rcpA* predicted ATG start codon ( $P_{cat}$ ; *cat* gene promoter); (ii) Pcl-*rcpA* mutant, Pcl promoter and optimized ribosome binding site (rbs) inserted upstream of the *rcpA* CDS; and (iii) plasmid pRcpA, which contains the *rcpA* CDS cloned behind the *lac* promoter in the expression vector pSU2718. (B) Relative fold change in transcript level of *rcpA*, *csgD*, and *csgA* in *rcpA*-overexpressing mutants compared to wt MS7163 as determined by qRT-PCR. Total mRNA was extracted from bacteria grown on YESCA agar at 37°C for 24 h. Results are displayed as the mean log<sub>2</sub> FC with standard deviation from three independent replicates. (C) CR staining of wt MS7163, MS7163*csgA*, Tn5-03831, Pcl-*rcpA*, MS7163(pRcpA), and MS7163(pSU2718) [vector control] following growth on YESCA-CR agar. Strains were grown by spotting 5  $\mu$ l of an overnight culture on YESCA-CR agar and incubating for 24 h at 37°C. (D) Western blot analysis of CsgA performed using whole-cell lysates prepared from MS7163, MS7163*csgA*, Tn5-03831, Pcl-*rcpA*, MS7163(pRcpA), and MS7163(pSU2718). Bacteria were grown on YESCA agar for 24 h to induce curli production and treated with formic acid to dissolve polymerized CsgA. Anti-OmpA antibody was used as a loading control.

in Tn5-03831 decreased ~70- and ~4,000-fold, respectively. The abolishment of curli production by Tn5-03831 was also confirmed by its inability to bind CR and anti-CsgA Western blot analysis (Fig. 5C and D).

RcpA is a small 282-bp CDS that encodes a putative 93-amino-acid protein of unknown function. To demonstrate that increased expression of RcpA in Tn5-03831 abolished curli production, and rule out the possibility of polar effects or secondary mutations, we generated two types of RcpA-overexpressing strains: (i) Pcl-*rcpA*, which contained a strong constitutive promoter (Pcl) inserted immediately upstream of the *rcpA* CDS on the MS7163 chromosome and (ii) MS7163(pRcpA), which contained the *rcpA* gene cloned behind the *lac* promoter in plasmid pSU2718 (Fig. 5A). The transcript level of *rcpA* was strongly increased in Pcl-*rcpA* and MS7163(pRcpA) compared to wt MS7163 [log<sub>2</sub> fold changes (FCs) of 5.5 and 11.4 in Pcl-*rcpA* and MS7163(pRcpA), respectively] (Fig. 5B). In contrast, the transcription of *csgA* and *csgD* was significantly decreased in both strains [*csgA*, log<sub>2</sub> FCs of -13.9 and -7.3 in Pcl-*rcpA* and MS7163(pRcpA), respectively; *csgD*, log<sub>2</sub> FCs of -8.5 and -6.6 in Pcl-*rcpA* and MS7163(pRcpA), respectively]. Both Pcl-*rcpA* and MS7163(pRcpA) did not produce curli based on CR binding and anti-CsgA Western blot analysis (Fig. 5C and D).





**FIG 6** Overexpression of RcpA abolishes curli production in other *E. coli* strains. (A) CR staining of MS7163 and UTI89 in the absence and presence of plasmid pRcpA following growth on YESCA-CR agar. Strains were grown by spotting 5  $\mu$ l of an overnight culture on YESCA-CR agar and incubating for 24 h at 37°C. (B) Western blot analysis of CsgA performed using whole-cell lysates prepared from MS7163 and UTI89 in the absence and presence of plasmid pRcpA. Bacteria were grown on YESCA agar for 24 h to induce curli production and treated with formic acid to dissolve polymerized CsgA. Anti-OmpA antibody was used as a loading control.


**Repression of curli production by RcpA is not strain specific.** To extend our findings on the role of RcpA in curli production, we examined the impact of overexpression of RcpA in UPEC strain UTI89, which produces curli during growth at 28°C on YESCA-CR agar (12, 20). Transformation of UTI89 with plasmid pRcpA led to reduced binding to CR (Fig. 6A) and abolishment of CsgA production compared to wild-type UTI89 following growth on YESCA agar (Fig. 6B). Taken together, these results demonstrate that overexpression of RcpA causes repression of curli production, and this function is conserved in different UPEC strains.

**Mutation of *purF* and overexpression of RcpA attenuate colonization of the mouse urinary tract.** Given the impact of mutations in the purine biosynthesis pathway and overexpression of RcpA on curli production, we tested the ability of MS7163*purF* and Pcl-*rcpA* to survive in the mouse urinary tract using a competitive infection assay. Female C57BL/6 mice were infected with a 1:1 ratio of MS7163 to MS7163*purF* or MS7163 to Pcl-*rcpA* cultured statically in LB without salt, respectively, and colonization was assessed at 1 day postinfection. In these experiments, both the MS7163*purF* and Pcl-*rcpA* mutants were significantly outcompeted by wt MS7163 in the bladder and urine of infected mice (Fig. 7). No significant colonization of the kidneys was observed. Taken together, these data demonstrate that disruption of the purine *de novo* biosynthesis pathway and overexpression of RcpA, both of which abrogate curli production, result in attenuated colonization of the mouse urinary tract.

## DISCUSSION

Recent literature has established an increasing appreciation for the role of curli in UPEC virulence (20, 21, 23, 47, 54). These amyloid fibers are produced by many UPEC strains at 37°C, mediate strong biofilm formation, confer resistance to the soluble cationic peptide LL-37, and enhance the production of proinflammatory mediators. Here, we characterized the role of curli in the virulent UPEC strain MS7163 and employed a forward genetic screen to identify new genes involved in the production of curli.

MS7163 was isolated in Slovakia from a patient with severe pyelonephritis (24). Whole-genome sequencing of MS7163 revealed it is most closely related to the neonatal meningitis-causing *E. coli* (NMEC) strain S88. *E. coli* S88 was isolated from the cerebrospinal fluid of a neonate and belongs to the highly virulent O45:K1:H7 clone, which accounts for one-third of all neonatal meningitis cases in France (50). Based on *in silico* analysis, MS7163 also possesses this serotype, and both strains share a large plasmid (pMS7163A and pECOS88, respectively) that harbors multiple virulence genes, including three iron uptake systems. Our analysis of the MS7163 genome revealed it contains a mutation in the essential cellulose synthase gene *bcsA* that results in the inability to produce cellulose. Intriguingly, S88 also contains exactly the same mutation,



**FIG 7** Mutation of *purF* and overexpression of RcpA attenuate colonization of the mouse urinary tract. Competitive mixed-infection mouse experiment employing a 1:1 mixture of MS7163 versus MS7163*purF* and MS7163 versus Pcl-*rcpA*. (Left panels) Total CFU enumerated from the bladder (A) and urine (B) of infected mice. Each symbol represents the CFU for each mouse, and the median is represented by a horizontal line. (Right panels) Competitive fitness indices of (A) bladder and (B) urine colonization. Each symbol represents data from an individual mouse in either urine or bladder tissue at 24 h postinfection. Logarithmic values of competitive indices are plotted on the y axis; horizontal bars represent median values. A  $\log_{10}$  fitness index below 0 (shown by the dashed line) indicates that MS7163*purF* and Pcl-*rcpA* were at a competitive disadvantage. Statistical significance was determined by the two-tailed Wilcoxon's signed rank test (\*,  $P < 0.05$ ).

a G deletion at nucleotide 556 of *bcsA* that causes its premature termination. Thus, we speculate that the production of curli, together with the inability to produce cellulose, might represent a previously unrecognized virulence feature of the O45:K1:H7 lineage. Given that the potent immune response stimulated by curli through the activation of interleukin-6 (IL-6) and IL-8 is amplified in the absence of cellulose (21, 23, 31), this phenotype is consistent with our hypothesis. Indeed, a link between the curli-positive, cellulose-negative phenotype and enhanced disease severity has also been demonstrated in the highly virulent *E. coli* O104:H4 outbreak strain that infected nearly 4,000 people and caused 54 deaths in Germany in 2011 (43).

Growth of MS7163 in LB without salt at 37°C promoted strong biofilm formation, which was abrogated in non-curli-inducing medium (LB broth) and by mutation of the *csgA* gene. We also demonstrated that sessile MS7163 cells were highly resistant to LL-37 compared to their free-swimming planktonic counterpart cells, thus providing direct experimental evidence that curli-mediated biofilm formation significantly enhances LL-37 resistance. LL-37 is a soluble antimicrobial peptide that forms an integral component of the host innate defense system of the urinary tract (23). Thus, curli production would be expected to enhance colonization of the urinary tract, and we demonstrated this in a mixed competitive infection model, where wt MS7163 outcompeted MS7163*csgA* at 24 h postinfection of the mouse bladder. These results were also consistent with previous data demonstrating a role for curli in the early stages (6 h postinfection) of bladder colonization in experimental mice (20).

The application of transposon mutagenesis together with TraDIS represents a powerful combinatorial approach to dissect genetic pathways linked to specific phenotypes (55–57). In this study, we screened ~132,000 mini-Tn5 mutants by using CR binding following growth on YESCA-CR agar as a proxy for curli production. Based on the size of the MS7163 genome and our previous analysis of unique insertion sites in

other TraDIS libraries (55, 57), we estimate this represents a coverage of approximately one insertion every 80 to 100 bp. Overall, two types of mutants were identified: those that were unable to bind CR (white colonies) and those that displayed reduced binding to CR (light red colonies). Using TraDIS, we then mapped the mini-Tn5 insertion sites of these mutants *en masse*, leading to the identification of 19 genes that were absolutely required for curli production and a further 22 genes that impacted curli production. Many of the genes identified in our screen overlapped with a recent large-scale screen of the *E. coli* K-12 Keio library (58). In addition to known structural and regulatory genes, these included genes involved in purine biosynthesis, lipopolysaccharide (LPS) biogenesis, stress, and stationary-phase regulation, metabolism, sodium transport, and septum formation. Despite this, we note there were also differences in the total list of genes identified in both studies (see Table S2 in the supplemental material), suggesting strain-specific variation, as well as differences in growth and temperature conditions, may account for divergence in the complex pathway of curli production.

We focused our experiments on genes that were absolutely required for curli production, all of which led to a “white” colony phenotype on YESCA-CR agar. Of the 19 genes identified in this category, three were integral to the curli operon (*csgA*, *csgB*, and *csgG*), and disruption of these genes has previously been shown to abolish curli production in *E. coli* (25–27, 58–60). We did not identify the curli gene *csgC*; however, this is consistent with other reports that show its mutation does not affect CR binding (26, 29, 58, 61–63). In addition, we did not find insertions in the curli chaperone genes *csgE* and *csgF* in our screen. Mutation of these genes has previously been linked to reduced CR binding, resulting in a light red colony phenotype following growth at  $\leq 28^{\circ}\text{C}$  on YESCA-CR agar (26, 29, 58, 61–63). It is possible that mutation of these genes in MS7163 led to a subtle change in CR binding phenotype that was missed in our screen or even that there were no insertions in either gene in our library. Interestingly, our screen also failed to identify the *csgD* regulator gene. We generated a targeted *csgD* mutant in MS7163 using  $\lambda$ -Red-mediated homologous recombination and confirmed it does not produce curli (data not shown). Closer examination of *csgD* revealed it contains a lower GC content (41.8%) than the entire MS7163 genome (50.7%), which could explain its absence from our screen as the mini-Tn5 transposon preferentially inserts into GC-rich regions (64). This has been observed in two previous TraDIS studies, where an increased mini-Tn5 transposon insertion frequency was detected in high-GC versus low-GC regions (57, 65). Consistent with current knowledge of curli gene control (35, 36, 42), we also identified *mlrA* (which encodes a master regulator of CsgD), *ihfA* and *ihfB* (which together encode IHF), and *ompR* (which encodes a regulator of envelope stress) as positive regulators of curli production, demonstrating their regulatory function is not subjected to temperature control.

In UPEC, purine *de novo* biosynthesis is required for IBC growth in the mouse bladder (66). Our TraDIS screen identified six genes within the purine biosynthesis operon that were required for curli production, and we confirmed the role of four of these genes (*purF*, *purD*, *purM*, and *purK*) by the construction of defined mutants and complementation. We hypothesize that disruption of *de novo* purine biosynthesis results in a decrease in the level of cyclic-di-GMP in the cell. Since cyclic-di-GMP activates the transcription of the *csgD* curli regulator gene (67), this would lead to abolishment of curli production in a *pur*-deficient background. Genes involved in purine biosynthesis were also recently shown to be required for curli production by *E. coli* K-12 (58), and mutation of *purF* attenuates the ability of UPEC UTI89 to colonize the bladder of C3H/HeN mice (66). Our study demonstrated attenuated bladder colonization by MS7163*purF* in C57BL/6 mice in a mixed competitive colonization experiment. The  $\log_{10}$  competitive index (CI) of wt MS7163 versus MS7163*purF* ( $-1.45$ ) was significantly lower than the  $\log_{10}$  CI of wt MS7163 versus MS7163*csgA* ( $-0.96$ ;  $P = 0.04$ ), suggesting that the attenuated colonization of MS7163*purF* may be due to the combined effect of reduced fitness via disruption of the purine *de novo* biosynthesis pathway and the inability to produce curli.

The *yrfF* gene was also identified in our screen, and we showed its mutation

abolishes curli production. Yrff, known as IgaA in *Salmonella enterica* serovar Typhimurium, is a negative regulator of the Rcs phosphorelay system, a complex signal transduction pathway that controls the production of colanic acid (51, 52, 68). The Rcs phosphorelay system consists of the histidine sensor kinase RcsC, the phosphoryl group transporter RcsD, and the response regulator RcsB (69). The outer membrane lipoprotein RcsF is also an integral activator of this system and functions by interacting with RcsC and Yrff, both of which are located in the cytoplasmic membrane (51, 52, 70). The *yrff* gene has been described as essential in several studies (51, 52, 55, 68, 71), as its mutation results in overactivation of RcsCDB and uncontrolled colonic acid biosynthesis (53, 69, 72). This lethal phenotype can be overcome by secondary suppressor mutations in *rscB*, *rscC*, and *rscD*, all of which affect the Rcs system (73). Here, we provide direct evidence for the role of Yrff in curli production through our screen, which identified seven independent insertions in *yrff* that abrogated CR binding, as well as the construction of a defined mutant (MS7163*yrff*) and its complementation. We also demonstrated an increase in the transcription of genes in the Rcs system, together with a corresponding decrease in curli gene transcription, in MS7163*yrff*. This result is consistent with studies in *E. coli* K-12 that showed the Rcs system negatively controls transcription of the *csg* genes (41). Although *yrff* was not essential in MS7163, we were unable to test the colonization of MS7163*yrff* in the mouse bladder, as static culture to enrich for the production of type 1 fimbriae led to spontaneous loss of its mucoid and noncurliated phenotype (see Table S3 in the supplemental material).

We have shown previously that the promoter of the chloramphenicol resistance gene in our mini-Tn5 transposon can drive the transcription of a downstream gene if the insertion position is favorable (57, 74). This led to the identification of the *rcaA* gene as a novel repressor of curli production. We confirmed this function by overexpression of RcaA using two independent systems: one based on insertion of a constitutive P<sub>CL</sub> promoter upstream of *rcaA* to drive strong transcription of the gene (P<sub>CL</sub>-*rcaA*) and a second based on plasmid-mediated overexpression [MS7163(pRcaA)]. In both cases, overexpression of RcaA led to significantly decreased transcription of curli genes (*csgD* and *csgA*), abolishment of CsgA expression, and the inability of the modified strains to bind CR. The P<sub>CL</sub>-*rcaA* strain was also attenuated in its capacity to colonize the mouse bladder in a mixed infection assay.

The *rcaA* gene encodes a protein 93 amino acids in length. Small proteins, notably those less than 100 amino acids, are frequently ignored due to difficulties in annotation and biochemical detection (75). However, examples of such proteins that localize to the inner membrane and regulate membrane-associated two-component sensor-kinase systems have been described (75). One of the best-characterized small proteins in *E. coli* is MgrB, a hydrophobic inner membrane protein that functions as a negative-feedback regulator of the PhoP/PhoQ system (76). Analysis of the translated RcaA protein sequence did not identify any known conserved domains or a putative signal sequence. However, using TMHMM2.0 (77), the RcaA protein is predicted to contain two transmembrane helices (amino acids 7 to 26 and 31 to 50) and a cytoplasmic C-terminal domain (amino acids 51 to 93). These properties, in addition to its high hydrophobic amino acid ratio, suggest RcaA may localize to the inner membrane like MgrB. Our analyses showed repression of curli synthesis by overexpression of RcaA was not strain specific and also occurred in UT189. While the precise mechanism by which RcaA represses curli synthesis remains to be elucidated, we demonstrated its overexpression led to decreased curli gene transcript levels. The *rcaA* gene is conserved in *E. coli*, *Shigella*, and *Achromobacter*, suggesting its function as a negative regulator of curli synthesis may be broadly conserved.

In summary, this study describes the complete genome sequence of UPEC MS7163, a curli-producing pyelonephritis strain. MS7163 belongs to the highly virulent O45:K1:H7 clone, and we provide the first description of curli production at 37°C by a strain from this lineage. We also describe the identification of several new genes involved in the production of curli and demonstrate their role in UPEC pathogenesis in experimen-

tal mice. Further work is now required to understand the precise molecular mechanisms by which these genes impact curli synthesis and the development of UTI.

## MATERIALS AND METHODS

**Ethics statement.** Approval for mouse infection studies was obtained from the University of Queensland Animal Ethics Committee (SCMB/242/16/NHMRC). Experiments were carried out in strict accordance with the recommendations in the Animal Care and Protection Act (Queensland, 2002) and the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (8th ed., 2013).

**Strains, growth conditions, and genome sequencing.** Bacterial strains and plasmids are listed in Data Set S2. Strains were grown at 37°C on solid or liquid lysogeny broth (LB) medium. To induce curli production, strains were cultured on YESCA agar (10 g/liter Casamino Acids, 1 g/liter yeast extract, 20 g/liter agar) or LB without salt supplemented with 50 µg/ml CR and 1 µg/ml Coomassie brilliant blue as indicated. When required, chloramphenicol (30 µg/ml), gentamicin (20 µg/ml), or IMP (0.5 mM) was added to the medium. Methods for MS7163 genome sequencing and analysis are described in Text S1 in the supplemental material.

**Transposon mutagenesis and TraDIS.** Generation of the transposon mutant library was performed essentially as previously described (55). MS7163 mini-Tn5 mutants were plated directly onto YESCA-CR agar supplemented with chloramphenicol and incubated at 37°C for 24 h. Under these growth conditions, CR binding was used as an indicator for curli production: curled colonies were red, mutants that produced less curli were light red, and mutants that did not produce curli were white. Mutants with an altered CR binding phenotype (i.e., white or light red colonies) were restreaked onto YESCA-CR agar over three successive rounds of subculture to confirm their phenotype and then stored individually in 20% glycerol at –80°C. Multiplex TraDIS analysis of pooled mutants was performed using the Illumina MiSeq platform as previously described (65). Tn5-specific reads were identified by FASTX-Toolkit (v.0.0.13) and mapped to the MS7163 complete genome using MAQ (v0.7.1) (78).

**Targeted gene mutation and complementation.** Specific mutants were generated using λ-Red-mediated homologous recombination as previously described (55, 79). Where necessary, the chloramphenicol resistance cassette was removed using plasmid pCP20 (80). Strain PCL-*rcpA* was generated using a previously described methodology (81). Plasmids for complementation were generated by PCR amplification and cloning of genes from MS7163 into plasmid pSU2718 and confirmed by sequencing. All primers are listed in Data Set S2.

**Transcription analysis and Western blotting.** To assess transcript levels of genes involved in curli production, strains were grown on YESCA agar for 24 h at 37°C, harvested directly, resuspended in KPi buffer (28.9 mM KH<sub>2</sub>PO<sub>4</sub> and 21.1 mM K<sub>2</sub>HPO<sub>4</sub>, pH 7.2) and standardized to an optical density at 600 nm (OD<sub>600</sub>) of 1. A volume of 500 µl of this bacterial suspension was added to 1 ml of RNAprotect bacterial reagent (Qiagen) to stabilize total RNA. RNA extraction, conversion to cDNA, and quantitative reverse transcription-PCR (qRT-PCR) were performed as previously described (82). All primers are listed in Data Set S2. The relative transcript level of target genes from each mutant was compared to wt MS7163 using *gapA* as a control. Relative transcript levels were calculated by the threshold cycle ( $2^{-\Delta\Delta CT}$ ) method (83) and are presented on a log<sub>2</sub> scale (log<sub>2</sub> FC) (84). Western blotting for the major curli subunit CsgA was performed following growth in YESCA agar for 24 h at 37°C as described previously (85).

**Biofilm analyses.** Biofilm assays were performed using polyvinyl chloride microplate plates (Corning) and growth in LB or LB without salt with subsequent crystal violet staining as previously described (85). To compare the sensitivity of sessile (biofilm) cells versus planktonic cells to LL-37, MS7163 biofilms were established following growth in LB without salt at 37°C for 24 h. Planktonic cells were removed, and the biofilm was washed 3 times with phosphate-buffered saline (PBS). One set of biofilm cells were incubated in LB for 2 h at 37°C, while another set were incubated in LB containing 64 µg/ml of LL-37 for 2 h at 37°C. After incubation, the biofilm was washed with 1× PBS, cells were detached from the biofilm by repeated pipetting and resuspended in 1× PBS, and the total CFU were enumerated by plating on LB agar. In parallel, planktonic cells were centrifuged, resuspended in either LB or LB containing 64 µg/ml of LL-37, and incubated for 2 h at 37°C, and the total CFU were enumerated by plating on LB agar. The difference in survival rates of planktonic and biofilm cells following incubation with LL-37 was analyzed by *t* test.

**Mouse model of UTI.** The C57BL/6 mouse model of ascending UTI was employed as previously described (16, 86). Strains were enriched for expression of type 1 fimbriae by three successive rounds of static growth in LB without salt for 48 h followed by one round of static growth for 24 h for inoculum preparation and did not display any difference in type 1 fimbria production as assessed by yeast cell agglutination and a *fim* switch orientation PCR (see Fig. S3 in the supplemental material). Curli expression was confirmed by dot blot analysis with CsgA antibody. Infections were performed as competitive assays; the inoculum contained 1:1 strain mixture of wt MS7163 versus MS7163*csgA*, MS7163*purF*, or PCL-*rcpA*. Bacterial loads corresponding to each strain in the urine, bladder, and kidney at 24 hours postinfection (hpi) were enumerated by plating onto LB agar and LB agar supplemented with chloramphenicol. Competitive indices were determined as the ratio of each respective mutant versus wt MS7163 to the ratio of the two strains in the inoculum. Statistical analyses were performed using the two-tailed Wilcoxon matched-pair signed-rank test (Prism7; GraphPad).

**Accession number(s).** The sequences for the MS7163 chromosome and plasmids pMS7163A and pMS7163B have been deposited in the NCBI GenBank database under GenBank accession no. [CP026853](#), [CP026854](#), and [CP026855](#), respectively. The raw PacBio sequence reads have been deposited in the sequence Read Archive (SRA) under accession no. [SRR6727962](#). The TraDIS reads have been deposited at the SRA under accession no. [SRR6706193](#), [SRR6706194](#), [SRR6706195](#), and [SRR6706196](#).

## SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/mBio.01462-18>.

**TEXT S1**, DOCX file, 0.1 MB.

**FIG S1**, TIF file, 8.1 MB.

**FIG S2**, TIF file, 1.6 MB.

**FIG S3**, TIF file, 1.6 MB.

**TABLE S1**, XLSX file, 0.1 MB.

**TABLE S2**, XLSX file, 0.1 MB.

**TABLE S3**, XLSX file, 0.1 MB.

**DATA SET S1**, XLSX file, 0.1 MB.

**DATA SET S2**, XLSX file, 0.1 MB.

## ACKNOWLEDGMENTS

We thank Barbara Arnts for technical assistance with the mouse UTI model.

This work was supported by grants from the National Health and Medical Research Council (NHMRC) of Australia. M.A.S. is supported by an NHMRC Senior Research Fellowship (GNT1106930), S.A.B. is supported by an NHMRC Career Development Fellowship (GNT1090456), M.R.C. is supported by NIH GM118651, and N.T.K.N. is supported by an Australian Government Research Training Program Scholarship. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

## REFERENCES

- Foxman B. 2014. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. *Infect Dis Clin North Am* 28:1–13. <https://doi.org/10.1016/j.idc.2013.09.003>.
- Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. 2015. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nat Rev Microbiol* 13:269–284. <https://doi.org/10.1038/nrmicro.3432>.
- Zowawi HM, Harris PN, Roberts MJ, Tambyah PA, Schembri MA, Pezzani MD, Williamson DA, Paterson DL. 2015. The emerging threat of multidrug-resistant Gram-negative bacteria in urology. *Nat Rev Urol* 12:570–584. <https://doi.org/10.1038/nrurol.2015.199>.
- Sabir N, Ikram A, Zaman G, Satti L, Gardezi A, Ahmed A, Ahmed P. 2017. Bacterial biofilm-based catheter-associated urinary tract infections: causative pathogens and antibiotic resistance. *Am J Infect Control* 45:1101–1105. <https://doi.org/10.1016/j.ajic.2017.05.009>.
- Trautner BW, Darouiche RO. 2004. Role of biofilm in catheter-associated urinary tract infection. *Am J Infect Control* 32:177–183. <https://doi.org/10.1016/j.ajic.2003.08.005>.
- Saint S, Chenoweth CE. 2003. Biofilms and catheter-associated urinary tract infections. *Infect Dis Clin North Am* 17:411–432. [https://doi.org/10.1016/S0891-5520\(03\)00011-4](https://doi.org/10.1016/S0891-5520(03)00011-4).
- Hannan TJ, Totsika M, Mansfield KJ, Moore KH, Schembri MA, Hultgren SJ. 2012. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic *Escherichia coli* bladder infection. *FEMS Microbiol Rev* 36:616–648. <https://doi.org/10.1111/j.1574-6976.2012.00339.x>.
- Hunstad DA, Justice SS. 2010. Intracellular lifestyles and immune evasion strategies of uropathogenic *Escherichia coli*. *Annu Rev Microbiol* 64:203–221. <https://doi.org/10.1146/annurev.micro.112408.134258>.
- Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ. 2003. Intracellular bacterial biofilm-like pods in urinary tract infections. *Science* 301:105–107. <https://doi.org/10.1126/science.1084550>.
- Mulvey MA, Schilling JD, Martinez JJ, Hultgren SJ. 2000. Bad bugs and beleaguered bladders: interplay between uropathogenic *Escherichia coli* and innate host defenses. *Proc Natl Acad Sci U S A* 97:8829–8835. <https://doi.org/10.1073/pnas.97.16.8829>.
- Totsika M, Kostakioti M, Hannan TJ, Upton M, Beatson SA, Janetka JW, Hultgren SJ, Schembri MA. 2013. A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic *Escherichia coli* ST131. *J Infect Dis* 208:921–928. <https://doi.org/10.1093/infdis/jit245>.
- Hung C, Zhou Y, Pinkner JS, Dodson KW, Crowley JR, Heuser J, Chapman MR, Hadjifrangiskou M, Henderson JP, Hultgren SJ. 2013. *Escherichia coli* biofilms have an organized and complex extracellular matrix structure. *mBio* 4:e00645-13. <https://doi.org/10.1128/mBio.00645-13>.
- Sarkar S, Vagenas D, Schembri MA, Totsika M. 2016. Biofilm formation by multidrug resistant *Escherichia coli* ST131 is dependent on type 1 fimbriae and assay conditions. *Pathog Dis* 74:ftw013. <https://doi.org/10.1093/femspd/ftw013>.
- Chahales P, Thanassi DG. 2015. Structure, function, and assembly of adhesive organelles by uropathogenic bacteria. *Microbiol Spectr* <https://doi.org/10.1128/microbiolspec.UTI-0018-2013>.
- Heras B, Totsika M, Peters KM, Paxman JJ, Gee CL, Jarrott RJ, Perugini MA, Whitten AE, Schembri MA. 2014. The antigen 43 structure reveals a molecular Velcro-like mechanism of autotransporter-mediated bacterial clumping. *Proc Natl Acad Sci U S A* 111:457–462. <https://doi.org/10.1073/pnas.1311592111>.
- Ulett GC, Valle J, Beloin C, Sherlock O, Ghigo JM, Schembri MA. 2007. Functional analysis of antigen 43 in uropathogenic *Escherichia coli* reveals a role in long-term persistence in the urinary tract. *Infect Immun* 75:3233–3244. <https://doi.org/10.1128/IAI.01952-06>.
- Anderson GG, Goller CC, Justice S, Hultgren SJ, Seed PC. 2010. Polysaccharide capsule and sialic acid-mediated regulation promote biofilm-like intracellular bacterial communities during cystitis. *Infect Immun* 78:963–975. <https://doi.org/10.1128/IAI.00925-09>.
- Floyd KA, Moore JL, Eberly AR, Good JA, Shaffer CL, Zaver H, Almqvist F, Skaar EP, Caprioli RM, Hadjifrangiskou M. 2015. Adhesive fiber stratification in uropathogenic *Escherichia coli* biofilms unveils oxygen-mediated control of type 1 pili. *PLoS Pathog* 11:e1004697. <https://doi.org/10.1371/journal.ppat.1004697>.
- Hadjifrangiskou M, Gu AP, Pinkner JS, Kostakioti M, Zhang EW, Greene SE, Hultgren SJ. 2012. Transposon mutagenesis identifies uropathogenic *Escherichia coli* biofilm factors. *J Bacteriol* 194:6195–6205. <https://doi.org/10.1128/JB.01012-12>.
- Cegelski L, Pinkner JS, Hammer ND, Cusumano CK, Hung CS, Chorell E, Aberg V, Walker JN, Seed PC, Almqvist F, Chapman MR, Hultgren SJ. 2009. Small-molecule inhibitors target *Escherichia coli* amyloid biogenesis and biofilm formation. *Nat Chem Biol* 5:913–919. <https://doi.org/10.1038/nchembio.242>.
- Bian Z, Brauner A, Li Y, Normark S. 2000. Expression of and cytokine activation by *Escherichia coli* curli fibers in human sepsis. *J Infect Dis* 181:602–612. <https://doi.org/10.1086/315233>.

22. Tursi SA, Lee EY, Medeiros NJ, Lee MH, Nicastro LK, Buttaro B, Gallucci S, Wilson RP, Wong GCL, Tükel Ç. 2017. Bacterial amyloid curli acts as a carrier for DNA to elicit an autoimmune response via TLR2 and TLR9. *PLoS Pathog* 13:e1006315. <https://doi.org/10.1371/journal.ppat.1006315>.
23. Kai-Larsen Y, Lühje P, Chromek M, Peters V, Wang X, Holm A, Kádas L, Hedlund KO, Johansson J, Chapman MR, Jacobson SH, Römling U, Agerberth B, Brauner A. 2010. Uropathogenic *Escherichia coli* modulates immune responses and its curli fimbriae interact with the antimicrobial peptide LL-37. *PLoS Pathog* 6:e1001010. <https://doi.org/10.1371/journal.ppat.1001010>.
24. Chromek M, Slamová Z, Bergman P, Kovács L, Podracká L, Ehrén I, Hökfelt T, Gudmundsson GH, Gallo RL, Agerberth B, Brauner A. 2006. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. *Nat Med* 12:636–641. <https://doi.org/10.1038/nm1407>.
25. Chapman MR, Robinson LS, Pinkner JS, Roth R, Heuser J, Hammar M, Normark S, Hultgren SJ. 2002. Role of *Escherichia coli* curli operons in directing amyloid fiber formation. *Science* 295:851–855. <https://doi.org/10.1126/science.1067484>.
26. Hammar M, Arnqvist A, Bian Z, Olsén A, Normark S. 1995. Expression of two *csg* operons is required for production of fibronectin- and Congo red-binding curli polymers in *Escherichia coli* K-12. *Mol Microbiol* 18: 661–670. [https://doi.org/10.1111/j.1365-2958.1995.mmi\\_18040661.x](https://doi.org/10.1111/j.1365-2958.1995.mmi_18040661.x).
27. Goyal P, Krasteva PV, Van Gerven N, Gubellini F, Van den Broek I, Troupiotis-Tsailaki A, Jonckheere W, Pehau-Arnaudet G, Pinkner JS, Chapman MR, Hultgren SJ, Howorka S, Fronzes R, Remaut H. 2014. Structural and mechanistic insights into the bacterial amyloid secretion channel CsgG. *Nature* 516:250–253. <https://doi.org/10.1038/nature13768>.
28. Chorell E, Andersson E, Evans ML, Jain N, Göthesson A, Åden J, Chapman MR, Almqvist F, Wittung-Stafshede P. 2015. Bacterial chaperones CsgE and CsgC differentially modulate human alpha-synuclein amyloid formation via transient contacts. *PLoS One* 10:e0140194. <https://doi.org/10.1371/journal.pone.0140194>.
29. Evans ML, Chorell E, Taylor JD, Åden J, Göthesson A, Li F, Koch M, Sefer L, Matthews SJ, Wittung-Stafshede P, Almqvist F, Chapman MR. 2015. The bacterial curli system possesses a potent and selective inhibitor of amyloid formation. *Mol Cell* 57:445–455. <https://doi.org/10.1016/j.molcel.2014.12.025>.
30. Thongsomboon W, Serra DO, Possling A, Hadjineophytou C, Hengge R, Cegelski L. 2018. Phosphoethanolamine cellulose: a naturally produced chemically modified cellulose. *Science* 359:334–338. <https://doi.org/10.1126/science.aao4096>.
31. Wang X, Rochon M, Lamprokostopoulou A, Lünsdorf H, Nimtz M, Römling U. 2006. Impact of biofilm matrix components on interaction of commensal *Escherichia coli* with the gastrointestinal cell line HT-29. *Cell Mol Life Sci* 63:2352–2363. <https://doi.org/10.1007/s00018-006-6222-4>.
32. Mika F, Hengge R. 2014. Small RNAs in the control of RpoS, CsgD, and biofilm architecture of *Escherichia coli*. *RNA Biol* 11:494–507. <https://doi.org/10.4161/rna.28867>.
33. Arnqvist A, Olsén A, Normark S. 1994. Sigma S-dependent growth-phase induction of the *csgBA* promoter in *Escherichia coli* can be achieved in vivo by sigma 70 in the absence of the nucleoid-associated protein H-NS. *Mol Microbiol* 13:1021–1032. <https://doi.org/10.1111/j.1365-2958.1994.tb00493.x>.
34. Olsén A, Arnqvist A, Hammar M, Sukupolvi S, Normark S. 1993. The RpoS sigma factor relieves H-NS-mediated transcriptional repression of *csgA*, the subunit gene of fibronectin-binding curli in *Escherichia coli*. *Mol Microbiol* 7:523–536. <https://doi.org/10.1111/j.1365-2958.1993.tb01143.x>.
35. Brown PK, Dozois CM, Nickerson CA, Zupparado A, Terlonge J, Curtiss R, III. 2001. MlrA, a novel regulator of curli (Agf) and extracellular matrix synthesis by *Escherichia coli* and *Salmonella enterica* serovar Typhimurium. *Mol Microbiol* 41:349–363. <https://doi.org/10.1046/j.1365-2958.2001.02529.x>.
36. Ogasawara H, Yamamoto K, Ishihama A. 2010. Regulatory role of MlrA in transcription activation of *csgD*, the master regulator of biofilm formation in *Escherichia coli*. *FEMS Microbiol Lett* 312:160–168. <https://doi.org/10.1111/j.1574-6968.2010.02112.x>.
37. Prigent-Combaret C, Brombacher E, Vidal O, Ambert A, Lejeune P, Landini P, Dorel C. 2001. Complex regulatory network controls initial adhesion and biofilm formation in *Escherichia coli* via regulation of the *csgD* gene. *J Bacteriol* 183:7213–7223. <https://doi.org/10.1128/JB.183.24.7213-7223.2001>.
38. Römling U, Bian Z, Hammar M, Sierralta WD, Normark S. 1998. Curli fibers are highly conserved between *Salmonella typhimurium* and *Escherichia coli* with respect to operon structure and regulation. *J Bacteriol* 180: 722–731.
39. Dorel C, Vidal O, Prigent-Combaret C, Vallet I, Lejeune P. 1999. Involvement of the Cpx signal transduction pathway of *E. coli* in biofilm formation. *FEMS Microbiol Lett* 178:169–175. <https://doi.org/10.1111/j.1574-6968.1999.tb13774.x>.
40. Ferrières L, Clarke DJ. 2003. The RcsC sensor kinase is required for normal biofilm formation in *Escherichia coli* K-12 and controls the expression of a regulon in response to growth on a solid surface. *Mol Microbiol* 50:1665–1682. <https://doi.org/10.1046/j.1365-2958.2003.03815.x>.
41. Vianney A, Jubelin G, Renault S, Dorel C, Lejeune P, Lazzaroni JC. 2005. *Escherichia coli* *tol* and *rcs* genes participate in the complex network affecting curli synthesis. *Microbiology* 151:2487–2497. <https://doi.org/10.1099/mic.0.27913-0>.
42. Gerstel U, Park C, Römling U. 2003. Complex regulation of *csgD* promoter activity by global regulatory proteins. *Mol Microbiol* 49:639–654. <https://doi.org/10.1046/j.1365-2958.2003.03594.x>.
43. Richter AM, Povolotsky TL, Wieler LH, Hengge R. 2014. Cyclic-di-GMP signalling and biofilm-related properties of the Shiga toxin-producing 2011 German outbreak *Escherichia coli* O104:H4. *EMBO Mol Med* 6:1622–1637. <https://doi.org/10.15252/emmm.201404309>.
44. Raterman EL, Shapiro DD, Stevens DJ, Schwartz KJ, Welch RA. 2013. Genetic analysis of the role of *yfiR* in the ability of *Escherichia coli* GFT073 to control cellular cyclic dimeric GMP levels and to persist in the urinary tract. *Infect Immun* 81:3089–3098. <https://doi.org/10.1128/IAI.01396-12>.
45. Lindenberg S, Klauck G, Pesavento C, Klauck E, Hengge R. 2013. The EAL domain protein *YciR* acts as a trigger enzyme in a c-di-GMP signalling cascade in *E. coli* biofilm control. *EMBO J* 32:2001–2014. <https://doi.org/10.1038/emboj.2013.120>.
46. Kader A, Simm R, Gerstel U, Morr M, Römling U. 2006. Hierarchical involvement of various GGDEF domain proteins in rdar morphotype development of *Salmonella enterica* serovar Typhimurium. *Mol Microbiol* 60:602–616. <https://doi.org/10.1111/j.1365-2958.2006.05123.x>.
47. Hung C, Marshall J, Burnham CA, Byun AS, Henderson JP. 2014. The bacterial amyloid curli is associated with urinary source bloodstream infection. *PLoS One* 9:e86009. <https://doi.org/10.1371/journal.pone.0086009>.
48. Chen SL, Hung CS, Xu J, Reigstad CS, Magrini V, Sabo A, Blasiar D, Bieri T, Meyer RR, Ozersky P, Armstrong JR, Fulton RS, Latreille JP, Spieth J, Hooton TM, Mardis ER, Hultgren SJ, Gordon JI. 2006. Identification of genes subject to positive selection in uropathogenic strains of *Escherichia coli*: a comparative genomics approach. *Proc Natl Acad Sci U S A* 103:5977–5982. <https://doi.org/10.1073/pnas.0600938103>.
49. Johnson TJ, Kariyawasam S, Wannemuehler V, Mangiamale P, Johnson SJ, Doetkott C, Skyberg JA, Lynne AM, Johnson JR, Nolan LK. 2007. The genome sequence of avian pathogenic *Escherichia coli* strain O1:K1:H7 shares strong similarities with human extraintestinal pathogenic *E. coli* genomes. *J Bacteriol* 189:3228–3236. <https://doi.org/10.1128/JB.01726-06>.
50. Bonacorsi S, Clermont O, Houdouin V, Cordevant C, Brahimi N, Marecat A, Tinsley C, Nassif X, Lange M, Bingen E. 2003. Molecular analysis and experimental virulence of French and North American *Escherichia coli* neonatal meningitis isolates: identification of a new virulent clone. *J Infect Dis* 187:1895–1906. <https://doi.org/10.1086/375347>.
51. Sato T, Takano A, Hori N, Izawa T, Eda T, Sato K, Umekawa M, Miyagawa H, Matsumoto K, Muramatsu-Fujishiro A, Matsumoto K, Matsuoka S, Hara H. 2017. Role of the inner-membrane histidine kinase RcsC and outer-membrane lipoprotein RcsF in the activation of the Rcs phosphorelay signal transduction system in *Escherichia coli*. *Microbiology* 163: 1071–1080. <https://doi.org/10.1099/mic.0.000483>.
52. Cano DA, Domínguez-Bernal G, Tierrez A, García-Del Portillo F, Casadesús J. 2002. Regulation of capsule synthesis and cell motility in *Salmonella enterica* by the essential gene *igaA*. *Genetics* 162:1513–1523.
53. Miskinyte M, Sousa A, Ramiro RS, de Sousa JA, Kotlinowski J, Caramalho I, Magalhães S, Soares MP, Gordo I. 2013. The genetic basis of *Escherichia coli* pathoadaptation to macrophages. *PLoS Pathog* 9:e1003802. <https://doi.org/10.1371/journal.ppat.1003802>.
54. Bian Z, Yan ZQ, Hansson GK, Thorén P, Normark S. 2001. Activation of inducible nitric oxide synthase/nitric oxide by curli fibers leads to a fall in blood pressure during systemic *Escherichia coli* infection in mice. *J Infect Dis* 183:612–619. <https://doi.org/10.1086/318528>.
55. Phan MD, Peters KM, Sarkar S, Lukowski SW, Allsopp LP, Gomes Moriel D, Achard ME, Totsika M, Marshall VM, Upton M, Beatson SA, Schembri MA. 2013. The serum resistome of a globally disseminated multidrug resis-

- tant uropathogenic *Escherichia coli* clone. *PLoS Genet* 9:e1003834. <https://doi.org/10.1371/journal.pgen.1003834>.
56. Kakkanat A, Phan MD, Lo AW, Beatson SA, Schembri MA. 2017. Novel genes associated with enhanced motility of *Escherichia coli* ST131. *PLoS One* 12:e0176290. <https://doi.org/10.1371/journal.pone.0176290>.
  57. Goh KGK, Phan MD, Forde BM, Chong TM, Yin WF, Chan KG, Ulett GC, Sweet MJ, Beatson SA, Schembri MA. 2017. Genome-wide discovery of genes required for capsule production by uropathogenic *Escherichia coli*. *mBio* 8:e01558-17. <https://doi.org/10.1128/mBio.01558-17>.
  58. Smith DR, Price JE, Burby PE, Blanco LP, Chamberlain J, Chapman MR. 2017. The production of curli amyloid fibers is deeply integrated into the biology of *Escherichia coli*. *Biomolecules* 7:E75. <https://doi.org/10.3390/biom7040075>.
  59. Robinson LS, Ashman EM, Hultgren SJ, Chapman MR. 2006. Secretion of curli fibre subunits is mediated by the outer membrane-localized CsgG protein. *Mol Microbiol* 59:870–881. <https://doi.org/10.1111/j.1365-2958.2005.04997.x>.
  60. Hammer ND, Schmidt JC, Chapman MR. 2007. The curli nucleator protein, CsgB, contains an amyloidogenic domain that directs CsgA polymerization. *Proc Natl Acad Sci U S A* 104:12494–12499. <https://doi.org/10.1073/pnas.0703310104>.
  61. Evans ML, Chapman MR. 2014. Curli biogenesis: order out of disorder. *Biochim Biophys Acta* 1843:1551–1558. <https://doi.org/10.1016/j.bbamcr.2013.09.010>.
  62. Nenninger AA, Robinson LS, Hammer ND, Epstein EA, Badtke MP, Hultgren SJ, Chapman MR. 2011. CsgE is a curli secretion specificity factor that prevents amyloid fibre aggregation. *Mol Microbiol* 81:486–499. <https://doi.org/10.1111/j.1365-2958.2011.07706.x>.
  63. Nenninger AA, Robinson LS, Hultgren SJ. 2009. Localized and efficient curli nucleation requires the chaperone-like amyloid assembly protein CsgF. *Proc Natl Acad Sci U S A* 106:900–905. <https://doi.org/10.1073/pnas.0812143106>.
  64. Green B, Bouchier C, Fairhead C, Craig NL, Cormack BP. 2012. Insertion site preference of Mu, Tn5, and Tn7 transposons. *Mob DNA* 3:3. <https://doi.org/10.1186/1759-8753-3-3>.
  65. Hancock SJ, Phan MD, Peters KM, Forde BM, Chong TM, Yin WF, Chan KG, Paterson DL, Walsh TR, Beatson SA, Schembri MA. 2017. Identification of IncA/C plasmid replication and maintenance genes and development of a plasmid multilocus sequence typing scheme. *Antimicrob Agents Chemother* 61:e01740-16. <https://doi.org/10.1128/AAC.01740-16>.
  66. Shaffer CL, Zhang EW, Dudley AG, Dixon BR, Guckes KR, Brelund EJ, Floyd KA, Casella DP, Algood HM, Clayton DB, Hadjifrangiskou M. 2016. Purine biosynthesis metabolically constrains intracellular survival of uropathogenic *E. coli*. *Infect Immun* 85:e00471-16. <https://doi.org/10.1128/IAI.00471-16>.
  67. Kim JK, Kwon JY, Kim SK, Han SH, Won YJ, Lee JH, Kim CH, Fukatsu T, Lee BL. 2014. Purine biosynthesis, biofilm formation, and persistence of an insect-microbe gut symbiosis. *Appl Environ Microbiol* 80:4374–4382. <https://doi.org/10.1128/AEM.00739-14>.
  68. Clarke DJ. 2010. The Rcs phosphorelay: more than just a two-component pathway. *Future Microbiol* 5:1173–1184. <https://doi.org/10.2217/fmb.10.83>.
  69. Majdalani N, Heck M, Stout V, Gottesman S. 2005. Role of RcsF in signaling to the Rcs phosphorelay pathway in *Escherichia coli*. *J Bacteriol* 187:6770–6778. <https://doi.org/10.1128/JB.187.19.6770-6778.2005>.
  70. Cho SH, Szewczyk J, Pesavento C, Zietek M, Banzhaf M, Roszczzenko P, Asmar A, Laloux G, Hov AK, Leverrier P, Van der Henst C, Vertommen D, Typas A, Collet JF. 2014. Detecting envelope stress by monitoring  $\beta$ -barrel assembly. *Cell* 159:1652–1664. <https://doi.org/10.1016/j.cell.2014.11.045>.
  71. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko KA, Tomita M, Wanner BL, Mori H. 2006. Construction of *Escherichia coli* K-12 in-frame, single-gene knockout mutants: the Keio collection. *Mol Syst Biol* 2:2006.0008. <https://doi.org/10.1038/msb4100050>.
  72. Meberg BM, Sailer FC, Nelson DE, Young KD. 2001. Reconstruction of *Escherichia coli* mrcA (PBP 1a) mutants lacking multiple combinations of penicillin binding proteins. *J Bacteriol* 183:6148–6149. <https://doi.org/10.1128/JB.183.20.6148-6149.2001>.
  73. Costa CS, Pettinari MJ, Méndez BS, Antón DN. 2003. Null mutations in the essential gene yrfF (mucM) are not lethal in rcsB, yojN or rcsC strains of *Salmonella enterica* serovar Typhimurium. *FEMS Microbiol Lett* 222: 25–32. [https://doi.org/10.1016/S0378-1097\(03\)00221-0](https://doi.org/10.1016/S0378-1097(03)00221-0).
  74. Phan MD, Nhu NTK, Achard MES, Forde BM, Hong KW, Chong TM, Yin WF, Chan KG, West NP, Walker MJ, Paterson DL, Beatson SA, Schembri MA. 2017. Modifications in the pmrB gene are the primary mechanism for the development of chromosomally encoded resistance to polymyxins in uropathogenic *Escherichia coli*. *J Antimicrob Chemother* 72: 2729–2736. <https://doi.org/10.1093/jac/dkx204>.
  75. Storz G, Wolf YI, Ramamurthi KS. 2014. Small proteins can no longer be ignored. *Annu Rev Biochem* 83:753–777. <https://doi.org/10.1146/annurev-biochem-070611-102400>.
  76. Lippa AM, Goulian M. 2009. Feedback inhibition in the PhoQ/PhoP signaling system by a membrane peptide. *PLoS Genet* 5:e1000788. <https://doi.org/10.1371/journal.pgen.1000788>.
  77. Sonnhammer EL, von Heijne G, Krogh A. 1998. A hidden Markov model for predicting transmembrane helices in protein sequences. *Proc Int Conf Intell Syst Mol Biol* 6:175–182.
  78. Li H, Ruan J, Durbin R. 2008. Mapping short DNA sequencing reads and calling variants using mapping quality scores. *Genome Res* 18: 1851–1858. <https://doi.org/10.1101/gr.078212.108>.
  79. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc Natl Acad Sci U S A* 97:6640–6645. <https://doi.org/10.1073/pnas.120163297>.
  80. Cherepanov PP, Wackernagel W. 1995. Gene disruption in *Escherichia coli*: TcR and KmR cassettes with the option of FLP-catalyzed excision of the antibiotic-resistance determinant. *Gene* 158:9–14. [https://doi.org/10.1016/0378-1119\(95\)00193-A](https://doi.org/10.1016/0378-1119(95)00193-A).
  81. Da Re S, Le Quéré B, Ghigo JM, Beloin C. 2007. Tight modulation of *Escherichia coli* bacterial biofilm formation through controlled expression of adhesion factors. *Appl Environ Microbiol* 73:3391–3403. <https://doi.org/10.1128/AEM.02625-06>.
  82. Sarkar S, Roberts LW, Phan MD, Tan L, Lo AW, Peters KM, Paterson DL, Upton M, Ulett GC, Beatson SA, Totsika M, Schembri MA. 2016. Comprehensive analysis of type 1 fimbriae regulation in fimB-null strains from the multidrug resistant *Escherichia coli* ST131 clone. *Mol Microbiol* 101:1069–1087. <https://doi.org/10.1111/mmi.13442>.
  83. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta CT}$  method. *Methods* 25:402–408. <https://doi.org/10.1006/meth.2001.1262>.
  84. Tan L, Moriel DG, Totsika M, Beatson SA, Schembri MA. 2016. Differential regulation of the surface-exposed and secreted SslE lipoprotein in extraintestinal pathogenic *Escherichia coli*. *PLoS One* 11:e0162391. <https://doi.org/10.1371/journal.pone.0162391>.
  85. Zhou Y, Smith DR, Hufnagel DA, Chapman MR. 2013. Experimental manipulation of the microbial functional amyloid called curli. *Methods Mol Biol* 966:53–75. [https://doi.org/10.1007/978-1-62703-245-2\\_4](https://doi.org/10.1007/978-1-62703-245-2_4).
  86. Sarkar S, Ulett GC, Totsika M, Phan MD, Schembri MA. 2014. Role of capsule and O antigen in the virulence of uropathogenic *Escherichia coli*. *PLoS One* 9:e94786. <https://doi.org/10.1371/journal.pone.0094786>.